# Pneumococcal Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/pneumococcal-disease

> 10 upcoming FDA catalysts in pneumococcal Disease: pg4 (PFE) on Mar to Jun 2027 (topline data readout); pg4 (PFE) on March 2027 (primary completion); pg4 multivalent vaccine (PFE) on Apr to Jul 2027 (topline data readout); pg4 multivalent vaccine (PFE) on April 2027 (primary completion); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 20, 2025 | [20-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/20-valent-pneumococcal-conjugate-vaccine) | PFE | Pneumococcal Disease | completed | "NCT05512819 (A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-09-20 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05512819)) |
| February 9, 2026 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | completed | "NCT06531538 (A Study to Learn About How a New Pneumococcal Vaccine Works in Children): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-09 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06531538)) |
| September 17, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07284654 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284654)) |
| Sep to Dec 2026 | [PCV20 topline data readout](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | scheduled | "NCT07284654 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284654)) |
| October 21, 2026 | [31-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) | PCVX | Pneumococcal Disease | completed | "NCT07365826 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365826)) |
| Oct 2026 to Jan 2027 | [31-valent pneumococcal conjugate vaccine topline data readout](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) | PCVX | Pneumococcal Disease | scheduled | "NCT07365826 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365826)) |
| October 25, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07425392 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07425392)) |
| Oct 2026 to Jan 2027 | [PCV20 topline data readout](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | scheduled | "NCT07425392 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07425392)) |
| Mar to Jun 2027 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT06524414 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524414)) |
| March 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT06524414 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-04 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06524414)) |
| Apr to Jul 2027 | [Pg4 multivalent vaccine topline data readout](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) | PFE | Pneumococcal Disease | scheduled | "NCT07794748 (A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794748)) |
| April 2027 | [Pg4 multivalent vaccine primary completion](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) | PFE | Pneumococcal Disease | scheduled | "NCT07794748 (A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-04-26 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07794748)) |
| Dec 2027 to Mar 2028 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07660198 (Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07660198)) |
| December 2027 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07660198 (Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07660198)) |
| Dec 2028 to Mar 2029 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07573462 (A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573462)) |
| December 2028 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07573462 (A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-12-30 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07573462)) |
| Jun to Sep 2029 | [Pg4 topline data readout](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07629440 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07629440)) |
| June 2029 | [Pg4 primary completion](https://sec-api.dev/pdufa/pg4) | PFE | Pneumococcal Disease | scheduled | "NCT07629440 (A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07629440)) |

## Drugs

- [20-valent pneumococcal conjugate vaccine](https://sec-api.dev/pdufa/20-valent-pneumococcal-conjugate-vaccine) (PFE)
- [Pg4](https://sec-api.dev/pdufa/pg4) (PFE)
- [PCV20](https://sec-api.dev/pdufa/pcv20) (PCVX)
- [31-valent pneumococcal conjugate vaccine](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) (PCVX)
- [Pg4 multivalent vaccine](https://sec-api.dev/pdufa/pg4-multivalent-vaccine) (PFE)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/pneumococcal-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Pneumococcal Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/pneumococcal-disease

```bibtex
@misc{secapidev_indications_pneumococcal_disease_20261116,
  title        = {Pneumococcal Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/pneumococcal-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_pneumococcal_disease_20261116","title":"Pneumococcal Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/pneumococcal-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
